Acorn Capital Advisors, LLC reported 20 holdings worth US$366M as of Jun 30, 2026 (Form 13F)
As of Jun 30, 2026 · Filed Aug 14, 2026
Acorn Capital Advisors, LLC reported 20 holdings worth US$366M as of Jun 30, 2026. Largest: Cg Oncology, Inc., Trevi Therapeutics, Inc. and Candel Therapeutics, Inc. Filed Aug 14, 2026 (Form 13F).
- Holdings
- 20
- Value as reported
- US$366M
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|---|---|---|
| Cg Oncology, Inc. | 1.13M | US$80.4M | 21.9% |
| Trevi Therapeutics, Inc. | 2.14M | US$40M | 10.9% |
| Candel Therapeutics, Inc. | 3.5M | US$36M | 9.8% |
| Puma Biotechnology Inc | 4.13M | US$33.5M | 9.1% |
| Jade Biosciences, Inc. | 987K | US$21.9M | 6.0% |
| Bicara Therapeutics Inc. | 643K | US$19.1M | 5.2% |
| Karyopharm Therapeutics Inc. | 1.52M | US$14.8M | 4.0% |
| Onkure Therapeutics, Inc. | 2.84M | US$12.9M | 3.5% |
| Cybin, Inc. | 1.54M | US$10.2M | 2.8% |
| Protara Therapeutics, Inc. | 1.75M | US$6.69M | 1.8% |
| Aura Biosciences, Inc. | 929K | US$6.6M | 1.8% |
| Leonabio, Inc. | 635K | US$5.83M | 1.6% |
| Verastem, Inc. | 1.47M | US$5.61M | 1.5% |
| Whitehawk Therapeutics, Inc. | 1.14M | US$5.22M | 1.4% |
| Q32 Bio Inc. | 216K | US$2.75M | 0.75% |
| Jasper Therapeutics, Inc. | 1.44M | US$604K | 0.16% |
| Vyne Therapeutics Inc. | 1,425 | US$926 | <0.01% |
| Cardiff Oncology, Inc. | 0 | US$0 | 0.00% |
| Terns Pharmaceuticals, Inc. | 0 | US$0 | 0.00% |